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G.R.V. Prasad,1 Harpreet Kaur,1 Vanita Jain,1 Radhika Srinivasan2Clinical Practice Points
 Pseudomyxoma peritonei (PMP) is an uncommon tu-
mor presenting with mucinous ascites and pressure
symptoms. Females usually present with abdominal
distension and ovarian mass. Cytoreductive surgery
combined with hyperthermic intraperitoneal chemo-
therapy is the treatment of choice.
 Our patient had typical presentation of PMP who
presented with ovarian mass. Left ovary showed a big
tumor with mucinous ascites, and the appendix was
normal looking. Histopathology revealed the primary
appendiceal tumor, and mass in the ovary was
metastatic.
 This case report highlights the importance of
complete surgery including appendicectomy as
most of the times primary tumor arises from the
appendix.Clinical Ovarian and Other Gynecologic Cancer, Vol. 7, No. 1/2, 40-3 ª 2015 Elsevier Inc. All rights reserved.
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Pseudomyxoma peritonei (PMP) is an uncommon clinical
condition characterized by a slow and progressive accumulation of
peritoneal implants and mucinous ascites. Accumulation of mucin
in peritoneal cavity results in massive symptomatic distension of
abdomen. Twenty to thirty percent of female PMP patients present
with an ovarian mass found during the evaluation for lower
abdominal pain, a pelvic mass, menstruation problems, or infer-
tility.1,2 Although earlier there was controversy in nomenclature, it
is now generally accepted that PMP arises as a result of neoplastic
mucin-secreting cells with low-grade cytologic features dissemi-
nating within the peritoneal cavity. Appendiceal and ovarian neo-
plasms give rise to majority of the cases. We are presenting a case of
adnexal (ovarian) mass with PMP resulting from appendiceal
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A 45-year-old multiparous woman presented with gradually
progressive abdominal distension and loss of appetite and weight for
6 months. She had bronchial asthma and uterovaginal prolapse
for 10 years. There was no alteration in bowel or bladder function
or awareness of mass. She attained menopause 6 years ago, and
perimenopausal transition was smooth. She had 5-term vaginal
deliveries and used barrier contraception.
On examination, patient’s general condition was good with pulse
rate of 100/min, blood pressure of 140/80 mm Hg, and respiratory
rate 30/min with mild pallor. Chest auscultation revealed bilateral
rhonchi. Abdominal distention was present, with umbilicus everted,
and small umbilical hernia was seen with moderate amount of free
ﬂuid but no palpable mass. On local examination, second-degree
cervical descent with large rectocele and minimal cystocele was
noticed. Uterus was normal sized, and there was no palpable adnexal
mass. Paracentesis of approximately 30 mL revealed thick mucinous
ﬂuid. Preoperatively, she received salbutamol and ipratropium neb-
ulization, intravenous hydrocortisone, and deriphyllin along with
supportive treatment in consultation with pulmonologist for acute
exacerbation of bronchial asthma. She was planned for laparotomy
and taken up for surgery under high risk in view of bronchial asthma.
Preoperative investigations revealed hemoglobin of 8.0 g/dL, renal
and liver function tests were within normal limits, x-ray chest was
normal, pulmonary function tests showed mild obstruction, arterial
blood gas on room air (pH/pO2/pCO2/HCO3
/Base excess/SatO2)2212-9553/$ - see frontmatter ª 2015 Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.cogc.2014.11.002
Figure 2 Appendicular Tumor Showing Features of a
Borderline Mucinous Neoplasm (Hematoxylin-Eosin
Stain, Oil Immersion Microscopy 3200)was 7.41/145/32/20/4/99%, and CA-125 ¼ 29.6 U/mL. Peri-
toneal cytology was suggestive of PMP. The peritoneal cytology
showed thick mucinous material with a few scattered mucinous
epithelial cells having cytoplasmic vacuolation and eccentric nucleus
with bland chromatin admixed with a few macrophages. There was
no evidence of frank mucinous carcinoma. Ultrasonography
revealed normal liver, spleen, gall bladder, and both kidneys; uterus
normal size with thin endometrium; and large cystic mass in pelvis
with internal septations and heterogenous foci. Mass showed coarse
echotexture and was full of complex soft tissue echoes.
She underwent laparotomy under combined epidural and gen-
eral anesthesia. Five kilograms of mucinous ascetic ﬂuid was
drained. Uterus, both tubes, and right ovary were normal. Left
ovary was replaced by a tumor of 10  6 cm with capsule
ruptured and mucinous material coating the whole of peritoneal
cavity. Surface of liver, undersurface of diaphragm, and bilateral
paracolic gutters were free of tumor, and there were no palpable
retroperitoneal lymph nodes. Appendix was retrocecal 3  1 cm
and buried in adhesions. Total abdominal hysterectomy with
bilateral salpingo-oophorectomy and infracolic omentectomy and
appendicectomy was done. Small paraumbilical hernia defect of
2  2 cm was present, which was repaired. Peritoneal wash was
done with 5% dextrose. Pelvic ﬂoor repair was deferred because of
high risk of anesthesia with prolongation of surgery. Postoperative
period was uneventful, and she received intravenous amox-
yclavulanic acid and metronidazole. She was discharged on the
second postoperative day.
Histopathology revealed the following in the left ovary: mucinous
tumor, borderline malignant, and metastatic. Tumor deposits were
present on serosal aspect of left fallopian tube. Right ovary, right
tube, endomyometrium, and cervix were unremarkable. No tumor
deposits were seen on the omentum. Appendix showed mucinous
tumor of borderline malignancy. Peritoneum revealed PMP. Overall
features were suggestive of PMP, disseminated peritoneal adeno-
mucinosis type (Figures 1-4).
Postoperatively, she received 6 cycles of oxalplatinum and
5-ﬂourouracil and under regular follow-up.Figure 1 Ascitic Fluid Smear Showing Thick Mucinous
Material With Low Cellularity (Papanicolaou Stain, Oil
Immersion Microscopy 3100)Discussion
PMP is an enigmatic syndrome characterized by copious
production of mucinous ascites that, over time, ﬁlls the peritoneal
cavity. It is a rare condition, incidence being 1 per million per year.
Classically, it presents at laparotomy as “jelly belly.” The term was
coined by Werth in 1884 when he described the condition in
association with mucinous carcinoma of the ovary. In 1901,
Frankel described a case of PMP in association with a cyst of the
appendix. Deﬁnition, origin, etiology, and treatment of this
peculiar condition are controversial. There is a spectrum of disease
varying from mucinous cystadenomas of appendix to mucinous
cystadenocarcinoma arising anywhere in abdominal cavity.
Recently, it has been proposed that the term PMP syndrome be
strictly applied to a pathologically and prognostically homogenous
group of cases characterized by histologically benign peritoneal
tumors that are frequently associated with an appendiceal mucinous
adenoma and have a unique natural history. Pathologically, the
peritoneal mucinous lesions are termed “disseminated peritoneal
adenomucinosis” or simply adenomucinosis. Cases of peritonealFigure 3 Serosal Aspect of the Appendix Showing Thick
Mucinous Material Conﬁrming Pseudomyxoma
Peritonei (Hematoxylin-Eosin Stain, Oil Immersion
Microscopy 3200)
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Figure 4 Ovarian Tumor Showing Features of a Borderline
Mucinous Neoplasm (Hematoxylin-Eosin Stain, Oil
Immersion Microscopy 3200)
Adnexal Mass With Pseudomyxoma Peritonei
42 -carcinomatosis, regardless of the presence of abundant extracellular
mucin, are excluded from this deﬁnition.1-3In addition to appen-
diceal and ovarian tumor, PMP has been found to originate from
other intra-abdominal organs such as colon and rectum, stomach,
gall bladder and bile ducts, small intestine and urinary bladder,
lungs, breast, fallopian tube, and pancreas. Synchronous disease is
found in ovary and appendix in most females, and the disease is
reported to be more prevalent in females.1
PMP is not considered to be biologically aggressive as it does not
invade ormetastasize, but disease is invariably fatal as space required in
abdomen is eventually replaced bymucinous tumor, resulting in death
unless the disease is deﬁnitely treated.1,4 Clinical presentation is var-
ied, and most patients present with abdominal distension. In women,
most cases are diagnosed while being investigated for an ovarian mass
as happened in the present case. In a study by Sugarbaker et al., 27%
cases presented with suspected acute appendicitis, 23% with
increasing abdominal distension, and 14% as new-onset hernia. In
women, 39% cases were diagnosed while being evaluated for an
ovarian mass. A delay in diagnosis is common, and many patients are
labeled as irritable bowel syndrome for number of years before
deﬁnitive diagnosis.2,3 It has been shown that although PMP usually
manifests with a synchronous primary tumor (or an unknown pri-
mary), the interval between the discovery of the primary (appendiceal)
tumor and the clinical diagnosis of PMP can vary signiﬁcantly.2,3
With the availability of imaging techniques, diagnosis can be
suspected pre-operatively. Ultrasound has been reported to be useful
for the diagnosis of an appendiceal mucocele or PMP, however,
usually in combination with computerized tomography. Contrast-
enhanced computerized tomography (CECT) and magnetic
resonance imaging are the main modalities used. Computed
tomography with oral, rectal, and intravenous contrast remains the
gold standard for diagnostic imaging in PMP. CECT ﬁndings in
PMP are pathognomic with appropriate radiologic techniques. It
demonstrates the characteristic distribution pattern of mucinous
ascites which can be differentiated from normal (watery) ascites by
analyzing density properties (Hounsﬁeld units [HU]). Mucinous
ascites has a signiﬁcantly higher density image (5-20 HU) than
normal ascites ( 0 HU). Furthermore, it shows low attenuation ofClinical Ovarian and Other Gynecologic Cancer December 2014soft tissue masses with internal mottled densities, distinctive rim-like
calciﬁcations, and characteristic septae.5 Striking feature is the
relative sparing of small bowel and mesentery with small bowel
compartmentalized in the center of abdominal cavity by large
omental cake. There is a characteristic layer of tumor surrounding
and scalloping the diaphragmatic surface of the liver. Radiologic
ﬁndings which can point toward tumor inoperability include
segmental obstruction of small bowel and tumor masses greater than
5 cm on small bowel and mesentery of jejunum and ileum.6
Tumor markers are not of much use; both CA-125 and CEA
levels may be elevated. Many patients are erroneously interpreted as
advanced ovarian cancer or advanced metastatic intestinal carci-
noma. Current opinion regarding the pathophysiology of PMP
suggests that it usually originates as an adenoma in submucosa of
the appendix which eventually ruptures releasing mucus-containing
epithelial cells into peritoneal cavity. Over the years, primary tumor
grows little in size, but epithelial cells within the peritoneal cavity
continue to proliferate and produce large quantities of mucin. These
cells get redistributed in peritoneal cavity along the direction of
movement of ﬂuid and by gravity and concentrate at the normal
sites of peritoneal ﬂuid absorption. There is complete or near
complete absence of mucinous tumors on the intestinal surfaces
because of active movement during peristalsis, exceptions to this
being antrum of stomach and pylorus, the ileocecal region, and
rectosigmoid sites which are relatively ﬁxed.1-3
Pathologically, there is a spectrum of disease ranging from
adenomucinosis to adenocarcinoma or there may be an adenomae-
carcinoma sequence such that the tumor may at some stage undergo
malignant transformation to a more aggressive variant. From a clin-
ical/pathologic point of view, PMP should always be regarded as
borderline malignant. Regarding the origin of concomitant mucinous
tumors of appendix and ovary, two theories has been proposed: they
either (1) arise as independent primaries or (2) represent an appen-
diceal primary tumor with metastasis to the ovaries, and various
studies have come to opposing conclusions regarding this.6 Various
objective methods used to resolve this issue include (1) application of
molecular genetic techniques, (2) analysis of c-ki-ras mutation
pattern, and (3) use of immunohistochemistry by using antibodies
that can discriminate between ovarian and colonic tumor. One of
these markers is cytokeratin-7 (CK-7) which is expressed in all
epithelial ovarian tumors but is absent inmost colonic tumors, and the
corresponding metastasis of these neoplasms maintains a similar
pattern of staining. Guerrieri et al.7 studied CK-7 expression in pri-
mary appendiceal mucinous tumor and simultaneous tumor of ap-
pendix and ovary and PMP and concluded that appendiceal
cystadenomas are CK-7 negative, whereas borderline mucinous
ovarian tumors are always CK-7 positive.William andHart8 in review
of mucinous tumors of the ovary revealed that PMP almost never
results from a ruptured primary ovarian mucinous neoplasm. In a
clinicopathologic study of 22 cases of mucinous tumors of ovary and
appendix by Young et al., it was seen that both tumors were syn-
chronous in 21 cases, and in 7 cases ovarian tumors were bilateral. In
20 cases, appendix was considered abnormal at operation, and in 2
cases, it appeared normal. Twenty-one patients had PMP. Micro-
scopically, ovarian and appendiceal tumors were of benign/borderline
malignancy. There were a number of features to suggest that ovarian
tumor in these cases was secondary to appendiceal tumor frequency of
G.R.V. Prasad et albilaterality of ovarian tumors, their right-sided predominance,
histologic similarity, presence of mucin, and atypical mucinous cells
on the ovarian surface.8 Jaffrey et al. supported an independent origin
of the ovarian and appendiceal tumors in clinicopathologic study of
25 cases. Majority of them had either a pelvic mass or abdominal/
pelvic pain. High frequency of bilateral ovarian tumors (11 of 25) and
right-sided predominance for unilateral ovarian tumors were found.4
The proper treatment for PMP remains uncertain because data
with a high level of evidence are lacking, but the combination of
(aggressive) surgical debulking with peritonectomy and hyperther-
mic intraperitoneal chemotherapy seems to improve the outcome.
Surgery is the mainstay of treatment for PMP. Radiotherapy has
little role because of unacceptable side effects from such a wide-ﬁeld
tumor. Systemic chemotherapy is not reliably effective because of
borderline malignancy of the cells and relatively poor blood supply.
Miner et al.9 reported a 10-year survival of 21% (12% disease free)
in 97 patients treated by serial debulking, systemic chemotherapy,
and/or delayed intermittent intraperitoneal 5-ﬂuorouracil over a
22-year period in Memorial Sloan Kettering. Traditional and still
practiced surgical approach is debulking surgery whereby, at
laparotomy, as much as possible of tumor is removed. Procedure
involves appendicectomy, omentectomy, and total hysterectomy
with bilateral salpingo-oophorectomy in females as was done in the
present case. Disease eventually recurs, and symptomatic recurrence
is treated by further laparotomy and debulking. But each repeated
procedure becomes ineffective and dangerous because of risk of
bowel injury and peritonitis. Alternative surgical approach is
complete tumor removal, stripping of parietal peritoneum, and
resecting intra-abdominal structures at ﬁxed sites that contain
tumor laden visceral peritoneum to accomplish complete
cytoreduction but morbidity and mortality from complete cytor-
eduction is high.1-3,10 Surgery is combined with intraperitoneal
intraoperative heated chemotherapy (HIIC) using agents like
5-ﬂourouracil/mitomycin.1-3 In a multi-institutional study of 2298
patients of PMP, Chua et al. had shown better progression-free
survival in patients who received hyperthermic intraperitoneal
chemotherapy (HIPEC). In a 12-year follow-up of 53 consecutive
patients of PMP, Vaira et al. described overall 5- and 10-year
survival of 94% and 84.6%, respectively, in patients treated with
cytoreductive surgery and HIPEC with acceptable morbidity.11,12
Owing to high morbidity and mortality of surgery, proper selec-
tion of patients is important. Radiologic ﬁndings which can point
toward tumor inoperability include segmental obstruction of small
bowel and tumor masses greater than 5 cm on small bowel and
mesentery of jejunum and ileum.5
Median survival of patients varies from months to years. The
estimated 1-, 2-, 5-, and 10- year survival rates has been shown to be98%, 86%, 53%, and 32% in one study, and outcome of tumor is
strongly associated with tumor biology.10 Various factors which were
shown to adversely affect patients’ survival were diffuse disease,
presence of abdominal distension, history of weight loss, invasion of
other organs, and use of systemic chemotherapy.3,10 Biological
behavior of the tumor (low-grade mucinous adenocarcinoma) and
history of complete cytoreductionwere independently associated with
prolonged survival.13 The natural history of PMP creates the potential
risk for recurrence or progression after macroscopic complete or
incomplete tumor removal. PMP patients who have been treated by
surgery, with or without (intraperitoneal) chemotherapy, should
therefore be monitored for progression or recurrence of disease.
To conclude, PMP is a rare condition which, though of
borderline malignancy, is invariably fatal and it follows an unre-
mitting and prolonged clinical course. There may be a diagnostic
dilemma regarding site of primary tumor especially in females who
present with ovarian masses. In most of the cases, ovarian mass is
the result of metastasis from some other primary, mostly appendi-
ceal. CECT scan is the best modality of diagnosis, and in many
cases, diagnosis and tumor operatability can be assessed with close
certainty on the basis of CECT ﬁndings. Optimal treatment
involves complete cytoreduction combined with HIIC.References
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